Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Urology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Available until 12/1/2023

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

Register Now
featured
Published in Urology

Journal Scan / Research · September 28, 2022

Five-Gene Signature–Based Model for the Prediction of Progression-Free Survival in Patients With Prostate Cancer

Frontiers in Oncology

 

 Save  Recommend
 Share

TAKE-HOME MESSAGE

  • The authors performed integrated transcriptome-wide gene expression analysis, using paired benign and malignant prostate samples from 9 patients with histologically confirmed prostate cancer, to develop and validate a novel gene signature–based risk model. They established a progression-free survival (PFS)–associated gene signature using a set of potential gene markers (PCBP1, PABPN1, PTPRF, DANCR, and MYC) highly associated with tumor status (AUC, 0.64–0.78). The authors developed a nomogram based on the gene signature and Gleason score parameters, which demonstrated improved prediction of PFS (AUC, 0.71–0.85) and was found to be superior to the Cambridge Prognostic Group model.
  • This model may have clinical utility as a prognostic tool for predicting PFS outcomes and may aid in the evaluation of treatment options for patients with prostate cancer.

abstract

This abstract is available on the publisher's site.

Access this abstract now  

Copyright © 2023 Elsevier Inc. All rights reserved.

Additional Info

Frontiers in Oncology
Gene expression analysis reveals a 5-gene signature for progression-free survival in prostate cancer
Front Oncol 2022 Sep 01;12(2022)914078, Z Mou, J Spencer, B Knight, J John, P McCullagh, JS McGrath, LW Harries

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Become a PracticeUpdate member now

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading

Recently Updated